ProfileGDS4814 / ILMN_1844326
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 28% 2% 18% 1% 4% 1% 1% 1% 17% 6% 4% 1% 1% 9% 1% 0% 1% 1% 7% 10% 1% 2% 4% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)45.205728
GSM780708Untreated after 4 days (C2_1)37.30852
GSM780709Untreated after 4 days (C3_1)43.091818
GSM780719Untreated after 4 days (C1_2)35.02051
GSM780720Untreated after 4 days (C2_2)38.68354
GSM780721Untreated after 4 days (C3_2)35.52041
GSM780710Trastuzumab treated after 4 days (T1_1)36.59731
GSM780711Trastuzumab treated after 4 days (T2_1)34.69781
GSM780712Trastuzumab treated after 4 days (T3_1)42.824317
GSM780722Trastuzumab treated after 4 days (T1_2)39.99766
GSM780723Trastuzumab treated after 4 days (T2_2)39.0044
GSM780724Trastuzumab treated after 4 days (T3_2)34.18571
GSM780713Pertuzumab treated after 4 days (P1_1)34.85211
GSM780714Pertuzumab treated after 4 days (P2_1)41.02239
GSM780715Pertuzumab treated after 4 days (P3_1)35.55371
GSM780725Pertuzumab treated after 4 days (P1_2)32.3310
GSM780726Pertuzumab treated after 4 days (P2_2)35.23841
GSM780727Pertuzumab treated after 4 days (P3_2)35.48511
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)40.36247
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)41.263210
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)35.3331
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)37.28812
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)38.83824